Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis

References

• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.
   PubMedGoogle Scholar
• Sini V, Cinieri S, Conte P, et al. Endocrine therapy in post-menopausal women with metastatic breast cancer: from literature and guidelines to clinical practice. Crit Rev OncolHematol. 2016;100:57–68.
   PubMed Web of Science ®Google Scholar
• Augereau P, Patsouris A, Bourbouloux E, et al. Hormono resistance inadvanced breast cancer: a new revolution in endocrine therapy. Ther Adv Med Oncol. 2017;9(5):335–346.
   PubMed Web of Science ®Google Scholar
• El Sayed R, El Jamal L, El Iskandarani S, et al. Share endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Front Oncol. 2019;9:510.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12:342–354.
   PubMed Web of Science ®Google Scholar
• Castaneda CA, Cortes-Funes H, Gomez HL, et al. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010;29:751–759.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018;11(1):80.
   PubMedGoogle Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–1936.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr, Toi M, Neven P, et al. the effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2019;6(1):116–124.
   Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal, growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524.
   PubMed Web of Science ®Google Scholar
• Kornblum N, Zhao F, Manola J, et al. Randomized Phase II trial offulvestrant plus everolimus or placebo in postmenopausal womenwith hormone receptor-positive, human epidermal growth factorreceptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36(16):1556–1563.
   PubMed Web of Science ®Google Scholar
• Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345–357.
   PubMed Web of Science ®Google Scholar
• Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor positive, aromatase inhibitor-resistant, advanced or metastatic breastcancer (FERGI): a randomised, double-blind, placebo-controlled, phase2 trial. Lancet Oncol. 2016;17(6):811–821.
   PubMed Web of Science ®Google Scholar
• Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904–916.
   PubMed Web of Science ®Google Scholar
• Campone M, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: overall survival results from BELLE-2. Eur J Cancer. 2018;103:147–154.
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Brown S, Hutton B, Clifford T, et al. A Microsoft-excel-based tool for running and critically appraising network meta-analyses–an overview and application of NetMetaXL. Syst Rev. 2014;3:110.
   PubMedGoogle Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641–656.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171.
   PubMed Web of Science ®Google Scholar
• Cancer. Net July 2020. [ cited 2020 Dec 20]. Available from: https://www.cancer.net/cancer-types/breast-cancer/statistics
   Google Scholar
• Cardoso F, Senkus E, Costa A, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29:1634–1657.
   PubMed Web of Science ®Google Scholar
• AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25(Suppl1):S18–S27.
   PubMedGoogle Scholar
• Presti D, Quaquarini E. The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2- metastatic breast cancer: biological mechanisms and new treatments. Cancers (Basel). 2019;11(9):1242.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer. Version 5. 2020.
   Google Scholar
• Zhang T, Feng F, Zhao W, et al. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis. Cancer Manag Res. 2018;10:5869–5880.
   PubMed Web of Science ®Google Scholar
• Jazieh KA, Budd GT, Dalpiaz N, et al. Can CDK4/6 inhibitors cause fatal lung injury? Expert Rev Anticancer Ther. 2019;19(11):917–919.
   PubMed Web of Science ®Google Scholar
• Mamiya H, Tahara RK, Tolaney SM, et al. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Ann Oncol. 2017;28(8):1825–1831.
   PubMed Web of Science ®Google Scholar
• Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2019;175(3):775–779.
   PubMed Web of Science ®Google Scholar
• Yiqun H, Jiayu W, Zijing W. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Curr Probl Cancer. 2020;100606. DOI:https://doi.org/10.1016/j.currproblcancer.2020.100606
   Google Scholar
• Ogata R , Kishino E , Wataru S, et al. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. Breast Cancer. 2021;28(1):206–215 .
   Web of Science ®Google Scholar
• Juric D, Ismail-Khan R, Campone M, et al. Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: safety, preliminary efficacy and molecular analysis. In: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio: Cancer Research; 2015.
   Google Scholar
• Forero A, Han H, Dees E, et al. Phase Ib study to assess the safety, tolerability and clinical activity of gedatolisib in combination with palbociclib and eitherletrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009). In: 2017 San Antonio Breast Cancer Symposium; San Antonio; 2017.
   Google Scholar